Benefit-risk assessment, clinical trial simulation and health impact modelling of new vaccines: epidemic preparedness and predictive analytics
(2x positions - Apr 2024 and Sep 2024 entries)
Background:
As part of the SCARDA (Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response) programme in Japan, the Vaccine Research and Development Center (VRDC), DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University aims to develop new vaccines against a range of infections, including high consequence infections (such as Ebola haemorrhagic fever) and tropical pathogens (such as dengue fever and leishmaniasis). However, it is not clear how these vaccines might be used in practice and how they may be tested.
Proposed project:
The research will involve reviewing the epidemiology of these target infections, and developing mathematical models of how they may spread. These models will be used to assess how the vaccines might be used to control the infections (e.g., responding to outbreaks of rare diseases or incorporated into routine immunisation programmes for common endemic infections) and to simulate clinical trial designs to assess different pathways to vaccine licensure. In addition, benefit risk-assessment of new vaccines will be conducted as part of epidemic preparedness, as well as health impact modelling of strategic vaccination scenarios. Potential research includes simulation case studies such as optimising dosing intervals for multi-dose regimens and extending use to lower-risk groups.
- Type
- PhD position
- Institution
- London School of Hygiene and Tropical Medicine & Nagasaki University
- City
- London / Nagasaki
- Country
- UK / Japan
- Closing date
- January 10th, 2024
- Posted on
- November 25th, 2023 06:58
- Last updated
- November 25th, 2023 06:58
- Share
- Tweet